StockNews.com assumed coverage on shares of 22nd Century Group (NASDAQ:XXII – Free Report) in a research report released on Friday. The firm issued a sell rating on the biotechnology company’s stock.
22nd Century Group Stock Up 10.7 %
NASDAQ:XXII opened at $0.29 on Friday. The company has a market cap of $2.39 million, a P/E ratio of 0.00 and a beta of 1.41. 22nd Century Group has a twelve month low of $0.24 and a twelve month high of $17.06. The business has a 50 day moving average price of $0.53 and a two-hundred day moving average price of $4.82.
22nd Century Group (NASDAQ:XXII – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.36) EPS for the quarter. 22nd Century Group had a negative net margin of 275.12% and a negative return on equity of 380.39%. The company had revenue of $7.95 million for the quarter.
Institutional Investors Weigh In On 22nd Century Group
22nd Century Group Company Profile
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Read More
- Five stocks we like better than 22nd Century Group
- Stock Market Sectors: What Are They and How Many Are There?
- The Average 401k Balance by Age Explained
- The 3 Best Blue-Chip Stocks to Buy Now
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Consumer Staples Stocks, Explained
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.